TICKERNOMICS Sign up
Last Update: 2024-12-27 15:21:49
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) https://www.alnylam.com
242.50USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ALNY
23.91%
SPY
32.66%
ALNY
43.75%
SPY
108.59%
ALNY
106.31%
SPY
302.52%
ALNY
150.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
31183.08
28689.34
0.35
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-93.85
15.48
963.81
0.05
0.00
-27039.90
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-18.30
99.07
-0.05
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.5712
-11.62
-5.27
0.34
Other Earnings and Cash Flow Stats:
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Net Income TTM ($MM) is -332.26
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Operating Income TTM ($MM) is -188.13
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Owners' Earnings Annual ($MM) is 79.22
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Current Price to Owners' Earnings ratio is 324.44
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) EBITDA TTM ($MM) is -65.28
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) EBITDA Margin is -0.05%
Capital Allocation:
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) has paid 0.00 dividends per share and bought back 2.746999 million shares in the past 12 months
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) has reduced its debt by 1072.378 million USD in the last 12 months
Capital Structure:
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Interest-bearing Debt ($MM) as of last quarter is 278
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Annual Working Capital Investments ($MM) are -355
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Book Value ($MM) as of last quarter is 32
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Debt/Capital as of last quarter is 859%
Other Balance Sheet Stats:
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) has 1099 million in cash on hand as of last quarter
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) has 1220 million of liabilities due within 12 months, and long term debt 1022 as of last quarter
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) has 128 common shares outstanding as of last quarter
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) has 0 million USD of preferred stock value
Academic Scores:
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Altman Z-Score is 3.05 as of last quarter
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) largest shareholder is owning shares at 0.00 ($MM) value
Garg Pushkal(an insider) Sold 1 shares of ALNYLAM PHARMACEUTICALS INC. ( ALNY ) for the amount of $255.80 on 2024-12-12
0.42% of ALNYLAM PHARMACEUTICALS INC. ( ALNY ) is held by insiders, and 95.64% is held by institutions
ALNYLAM PHARMACEUTICALS INC. ( ALNY ) went public on 2004-05-28
Other ALNYLAM PHARMACEUTICALS INC. ( ALNY ) financial metrics:
FCF:16.06
Unlevered Free Cash Flow:981.31
EPS:-3.47
Operating Margin:-18.30
Gross Profit Margin:99.07
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-1379.37
Beta:0.34
Buffet's Owners Earnings:79.22
Price to Owner's Earnings:324.44
About ALNYLAM PHARMACEUTICALS INC. ( ALNY ) :
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.